XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 29, 2024
Mar. 31, 2023
Statement of Cash Flows [Abstract]    
Net income $ 37,317 $ 40,028
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 6,378 6,855
Stock-based compensation 19,113 16,661
Non-cash lease expense 6,764 6,731
Acquired in-process research and development technology 19,500 36,500
Other, net 9,206 (3,743)
Changes in operating assets and liabilities:    
Trade receivables, net (3,170) (19,178)
Inventory 1,715 (8,370)
Prepaid expenses and other assets 10,075 10,372
Accrued collaboration liabilities (3,829) (1,864)
Accounts payable and other liabilities (34,247) 416
Net cash provided by operating activities 68,822 84,408
Cash flows from investing activities:    
Purchases of property, equipment and other, net (9,691) (12,024)
Acquired in-process research and development technology (8,500) (36,500)
Purchases of investments (138,468) (311,837)
Proceeds from maturities and sales of investments 268,452 310,769
Net cash provided by (used in) investing activities 111,793 (49,592)
Cash flows from financing activities:    
Payments for repurchases of common stock (185,375) 0
Proceeds from issuance of common stock under equity incentive plans 8,315 7,143
Taxes paid related to net share settlement of equity awards (6,988) (2,557)
Net cash provided by (used in) financing activities (184,048) 4,586
Net increase (decrease) in cash and cash equivalents (3,433) 39,402
Cash and cash equivalents at beginning of period 262,994 502,677
Cash and cash equivalents at end of period $ 259,561 $ 542,079